Deciding whether Atara Biotherapeutics (NASDAQ: ATRA) is an attractive investment depends on your tolerance for clinical-stage biotechnology risks. While its allogeneic T-cell immunotherapy platform holds substantial medical potential, the company faces pipeline execution and funding hurdles. What is your targeted investment horizon and risk threshold? Consulting a licensed financial advisor is recommended.